Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Update phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the.
CARISMA Therapeutics Completes Series B Financing Totaling $59 Million prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of .
Passage BioFebruary 8, 2021 GMT
- Phase 1/2 trial expected to commence in first half of 2021
- Company has three INDs cleared for rare monogenic CNS disorders
PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy being studied for the treatment of early infantile Krabbe disease (Globoid Cell Leukodystrophy). Currently, there are no approved disease-modifying therapies available for Krabbe disease, a rare lysosomal storage disease that most often
Press release content from Business Wire. The AP news staff was not involved in its creation.
Tmunity Announces Appointment of Jeffrey Leiden M.D., Ph.D. as Chairman of the Board of Directors
January 25, 2021 GMT
PHILADELPHIA (BUSINESS WIRE) Jan 25, 2021
Tmunity Therapeutics, Inc., a clinical-stage biotherapeutics company specifically designed to deliver on the bold promise to ‘uncancer the world’ by creating the best T cell medicines for solid tumor patients, today announced the appointment of Jeffrey Leiden, M.D., Ph.D., as Non-Executive Chairman of its Board of Directors.
“I am thrilled to welcome Jeff as Chair of our board of directors as 2021 will be a transformative year for Tmunity with our continued rapid advancement of our clinical and preclinical oncology portfolio. We wanted to bring on an equally transformative leader to chair our board, a physician-scientist who is passionate about translating scientific advances into breakthrough therapies for our patients,